These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 35496328)

  • 1. Design, synthesis,
    Aziz NAAM; George RF; El-Adl K; Mahmoud WR
    RSC Adv; 2022 Apr; 12(20):12913-12931. PubMed ID: 35496328
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Five and six membered heterocyclic rings endowed with azobenzene as dual EGFR
    Anwer KE; El-Hddad SSA; Abd El-Sattar NEA; El-Morsy A; Khedr F; Mohamady S; Keshek DE; Salama SA; El-Adl K; Hanafy NS
    RSC Adv; 2023 Nov; 13(50):35321-35338. PubMed ID: 38053688
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploration of thiazolidine-2,4-diones as tyrosine kinase inhibitors: Design, synthesis, ADMET, docking, and antiproliferative evaluations.
    Aziz NAAM; George RF; El-Adl K; Mahmoud WR
    Arch Pharm (Weinheim); 2023 Mar; 356(3):e2200465. PubMed ID: 36403198
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis, docking, ADMET and anticancer evaluations of
    Alsulaimany M; El-Adl K; Aljohani AKB; Alharbi HY; Alatawi OM; Aljohani MS; El-Morsy A; Almadani SA; Alsimaree AA; Salama SA; Keshek DE; Mohamed AA
    RSC Adv; 2023 Dec; 13(51):36301-36321. PubMed ID: 38093733
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Iodoquinazoline-derived VEGFR-2 and EGFR
    Mohamed AA; El-Hddad SSA; Aljohani AKB; Khedr F; Alatawi OM; Keshek DE; Ahmed S; Alsulaimany M; Almadani SA; El-Adl K; Hanafy NS
    Bioorg Chem; 2024 Feb; 143():107062. PubMed ID: 38150938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anticancer evaluations of iodoquinazoline substituted with allyl and/or benzyl as dual inhibitors of EGFR
    Aljohani AKB; El-Adl K; Almohaywi B; Alatawi OM; Alsulaimany M; El-Morsy A; Almadani SA; Alharbi HY; Aljohani MS; Abdulhaleem M FA; Osman HEM; Mohamady S
    RSC Adv; 2024 Mar; 14(12):7964-7980. PubMed ID: 38454937
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme.
    El-Helby AA; Sakr H; Ayyad RRA; El-Adl K; Ali MM; Khedr F
    Anticancer Agents Med Chem; 2018; 18(8):1184-1196. PubMed ID: 29651967
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 2-Thioxo-3,4-dihydropyrimidine and thiourea endowed with sulfonamide moieties as dual EGFR
    El-Gaby MSA; Abdel Reheim MAM; Akrim ZSM; Naguib BH; Saleh NM; El-Adasy ABAAM; El-Adl K; Mohamady S
    Drug Dev Res; 2024 Feb; 85(1):e22143. PubMed ID: 38349267
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis, docking, ADMET profile, and anticancer evaluations of novel thiazolidine-2,4-dione derivatives as VEGFR-2 inhibitors.
    El-Adl K; Sakr H; El-Hddad SSA; El-Helby AA; Nasser M; Abulkhair HS
    Arch Pharm (Weinheim); 2021 Jul; 354(7):e2000491. PubMed ID: 33788290
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, green synthesis, molecular docking and anticancer evaluations of diazepam bearing sulfonamide moieties as VEGFR-2 inhibitors.
    Saleh NM; El-Gaby MSA; El-Adl K; Abd El-Sattar NEA
    Bioorg Chem; 2020 Nov; 104():104350. PubMed ID: 33142416
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis, and docking of novel thiazolidine-2,4-dione multitarget scaffold as new approach for cancer treatment.
    Hanafy NS; Aziz NAAM; El-Hddad SSA; Abdelgawad MA; Ghoneim MM; Dawood AF; Mohamady S; El-Adl K; Ahmed S
    Arch Pharm (Weinheim); 2023 Jul; 356(7):e2300137. PubMed ID: 37147779
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis, molecular docking, anticancer evaluations, and in silico pharmacokinetic studies of novel 5-[(4-chloro/2,4-dichloro)benzylidene]thiazolidine-2,4-dione derivatives as VEGFR-2 inhibitors.
    El-Adl K; El-Helby AA; Sakr H; Ayyad RR; Mahdy HA; Nasser M; Abulkhair HS; El-Hddad SSA
    Arch Pharm (Weinheim); 2021 Feb; 354(2):e2000279. PubMed ID: 33073374
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 5-(4-Methoxybenzylidene)thiazolidine-2,4-dione-derived VEGFR-2 inhibitors: Design, synthesis, molecular docking, and anticancer evaluations.
    El-Adl K; Sakr H; Nasser M; Alswah M; Shoman FMA
    Arch Pharm (Weinheim); 2020 Sep; 353(9):e2000079. PubMed ID: 32515896
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis, molecular docking, and anticancer activity of benzoxazole derivatives as VEGFR-2 inhibitors.
    El-Helby AA; Sakr H; Eissa IH; Abulkhair H; Al-Karmalawy AA; El-Adl K
    Arch Pharm (Weinheim); 2019 Oct; 352(10):e1900113. PubMed ID: 31448458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis, in silico molecular docking, and ADMET studies of quinoxaline-isoxazole-piperazine conjugates as EGFR-targeting agents.
    Ali MI; Thirukovela NS; Kumar GB; Dasari G; Badithapuram V; Manchal R; Bandari S
    Chem Biol Drug Des; 2024 Mar; 103(3):e14499. PubMed ID: 38444047
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis and molecular docking of new [1,2,4] triazolo[4,3-a]quinoxaline derivatives as anticancer agents targeting VEGFR-2 kinase.
    Alsaif NA; Elwan A; Alanazi MM; Obaidullah AJ; Alanazi WA; Alasmari AF; Albassam H; Mahdy HA; Taghour MS
    Mol Divers; 2022 Aug; 26(4):1915-1932. PubMed ID: 34460053
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis, molecular docking and anticancer evaluations of 5-benzylidenethiazolidine-2,4-dione derivatives targeting VEGFR-2 enzyme.
    El-Adl K; El-Helby AA; Sakr H; Eissa IH; El-Hddad SSA; M I A Shoman F
    Bioorg Chem; 2020 Sep; 102():104059. PubMed ID: 32653608
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular Docking and In Vitro Anticancer Screening of Synthesized Arylthiazole linked 2H-indol-2-one Derivatives as VEGFR-2 Kinase Inhibitors.
    Shalmali N; Bawa S; Ali MR; Kalra S; Kumar R; Zeya B; Rizvi MA; Partap S; Husain A
    Anticancer Agents Med Chem; 2022; 22(11):2166-2180. PubMed ID: 34792005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, Molecular Docking, Synthesis, Anticancer and Anti-Hyperglycemic Assessments of Thiazolidine-2,4-diones Bearing Sulfonylthiourea Moieties as Potent VEGFR-2 Inhibitors and PPARĪ³ Agonists.
    Abdelgawad MA; El-Adl K; El-Hddad SSA; Elhady MM; Saleh NM; Khalifa MM; Khedr F; Alswah M; Nayl AA; Ghoneim MM; Abd El-Sattar NEA
    Pharmaceuticals (Basel); 2022 Feb; 15(2):. PubMed ID: 35215339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, synthesis, molecular docking and in silico ADMET profile of pyrano[2,3-d]pyrimidine derivatives as antimicrobial and anticancer agents.
    Abd El-Sattar NEA; El-Adl K; El-Hashash MA; Salama SA; Elhady MM
    Bioorg Chem; 2021 Oct; 115():105186. PubMed ID: 34314914
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.